Overview
Reticulate acropigmentation of Kitamura (RAK) is a rare inherited skin disorder characterized by a distinctive pattern of reticulate (net-like) hyperpigmented macules that primarily affect the dorsal surfaces of the hands and feet (acral areas). The condition was first described by the Japanese dermatologist Kitamura in 1943. It is also known as reticulate acropigmentation of Kitamura or Kitamura disease. The pigmented macules are typically small, slightly depressed, and arranged in a reticular pattern. Additional features may include pits or breaks in the epidermal ridges of the palms and soles (interrupted dermatoglyphics), which is considered a hallmark finding. Some patients may also develop pigmented macules on other body areas over time. The condition is caused by heterozygous loss-of-function mutations in the ADAM10 gene (a disintegrin and metalloproteinase domain 10), located on chromosome 15q21.3. ADAM10 plays a role in various cell signaling pathways, including Notch signaling, which is important for skin pigmentation and epidermal homeostasis. The onset of pigmentary changes typically begins in childhood, often in the first or second decade of life, and tends to progress slowly over time. The condition is generally benign and does not affect internal organs or overall health, though the cosmetic appearance can cause significant psychosocial distress. There is currently no curative treatment for reticulate acropigmentation of Kitamura. Management is primarily supportive and cosmetic. Sun protection is generally recommended to minimize further pigmentation. Topical depigmenting agents such as hydroquinone or retinoids have been tried with limited success. Laser therapies have been explored in some cases but results are variable and recurrence of pigmentation is common. Genetic counseling is recommended for affected individuals and their families given the autosomal dominant inheritance pattern.
Also known as:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Childhood
Begins in childhood, roughly ages 1 to 12
FDA & Trial Timeline
1 eventRAK Medical and Health Sciences University — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Reticulate acropigmentation of Kitamura.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Reticulate acropigmentation of Kitamura at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Reticulate acropigmentation of Kitamura.
Community
No community posts yet. Be the first to share your experience with Reticulate acropigmentation of Kitamura.
Start the conversation →Latest news about Reticulate acropigmentation of Kitamura
Disease timeline:
New recruiting trial: Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
A new clinical trial is recruiting patients for Reticulate acropigmentation of Kitamura
New recruiting trial: RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention
A new clinical trial is recruiting patients for Reticulate acropigmentation of Kitamura
New recruiting trial: The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
A new clinical trial is recruiting patients for Reticulate acropigmentation of Kitamura
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Reticulate acropigmentation of Kitamura
What is Reticulate acropigmentation of Kitamura?
Reticulate acropigmentation of Kitamura (RAK) is a rare inherited skin disorder characterized by a distinctive pattern of reticulate (net-like) hyperpigmented macules that primarily affect the dorsal surfaces of the hands and feet (acral areas). The condition was first described by the Japanese dermatologist Kitamura in 1943. It is also known as reticulate acropigmentation of Kitamura or Kitamura disease. The pigmented macules are typically small, slightly depressed, and arranged in a reticular pattern. Additional features may include pits or breaks in the epidermal ridges of the palms and sol
How is Reticulate acropigmentation of Kitamura inherited?
Reticulate acropigmentation of Kitamura follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Reticulate acropigmentation of Kitamura typically begin?
Typical onset of Reticulate acropigmentation of Kitamura is childhood. Age of onset can vary across affected individuals.
Which specialists treat Reticulate acropigmentation of Kitamura?
1 specialists and care centers treating Reticulate acropigmentation of Kitamura are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.